Xeno

 Xenoblade Chronicles: Definitive Edition Is Now Available on Nintendo Switch

Retrieved on: 
Friday, May 29, 2020
Technology, Mobile, Wireless, Electronic Games, MEN, Retail, Entertainment, Online, Mobile Entertainment, Consumer, Online Retail, General Entertainment, Teens, Children, Internet, Video game consoles, Video gaming, Video games, Role-playing video games, Handheld game consoles, Open world video games, Video games developed in Japan, Xenoblade Chronicles, Shulk, Xeno, Nintendo

Join Shulk as he courageously fights for the future and unravels the secrets of the powerful Monado blade in the Xenoblade Chronicles: Definitive Edition game, which is now available for the Nintendo Switch family of systems.

Key Points: 
  • Join Shulk as he courageously fights for the future and unravels the secrets of the powerful Monado blade in the Xenoblade Chronicles: Definitive Edition game, which is now available for the Nintendo Switch family of systems.
  • View the full release here: https://www.businesswire.com/news/home/20200529005131/en/
    Xenoblade Chronicles: Definitive Edition is now available at a suggested retail price of $59.99.
  • Xenoblade Chronicles: Definitive Edition is now available at a suggested retail price of $59.99.
  • About Nintendo: The worldwide pioneer in the creation of interactive entertainment, Nintendo Co., Ltd., of Kyoto, Japan, manufactures and markets hardware and software for its Nintendo Switch system and the Nintendo 3DS family of portable systems.

XenoTherapeutics Wins ABA’s Best Bioengineering Paper Award for Research on Xeno-Skin™, a Novel Xenotransplantation Treatment for Severe Burns

Retrieved on: 
Thursday, April 4, 2019
Health, Biotechnology, Other Health, Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Organ transplantation, Animal testing, Life extension, Xenotransplantation, Burns, Graft, Allotransplantation, Xeno

XenoTherapeutics, Inc., a regenerative medicine company specializing in xenotransplantation, received the Burke/Yannas Award for Best Bioengineering Paper today at the 51st conference of the American Burn Association for its research of Xeno-Skin.

Key Points: 
  • XenoTherapeutics, Inc., a regenerative medicine company specializing in xenotransplantation, received the Burke/Yannas Award for Best Bioengineering Paper today at the 51st conference of the American Burn Association for its research of Xeno-Skin.
  • Xeno-Skin is a first-of-its-kind xenotransplantation product, designed to provide a safe temporary coverage mechanism for patients with severe burn wounds.
  • The winning research demonstrated 30-day efficacy of Xeno-Skin on partial- and full-thickness burn wounds, equal to the duration of allograft comparators in preclinical trials.
  • Our goal is to advance the field of xenotransplantation to address a critical unmet need for treatment of severe burns.

RoosterBio Launches Thaw-and-Use RoosterRTP™ in a Xeno-Free Regulatory Friendly Product Format

Retrieved on: 
Thursday, December 20, 2018
Product management, Xeno, Product marketing, Product, Cryopreservation

This latest product addition, to accelerate clinical translation, is a high-volume hMSC vial and a product line extension of the first generation Ready-to-Print (RTP) product.

Key Points: 
  • This latest product addition, to accelerate clinical translation, is a high-volume hMSC vial and a product line extension of the first generation Ready-to-Print (RTP) product.
  • Now available in a xeno-free formulated (XFF) format, the cells and formulation are free from xeno-containing components and exhibit a more streamlined regulatory profile.
  • Comprised of cryopreserved human bone marrow-derived hMSCs, this product supports RoosterBio's development grade (RUO) product portfolio as a fully-expanded cell population.
  • The product is designed to specifically address the product development bottlenecks of the rapidly evolving Regenerative Medicine (RM) market.